Trial Profile
German Hepatitis C-Registry (DHC-R)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Daclatasvir (Primary) ; Dasabuvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Glecaprevir/pibrentasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir (Primary) ; Paritaprevir (Primary) ; Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Sofosbuvir/velpatasvir/voxilaprevir (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms DHC-R
- 24 Jun 2023 Results (n=2727, data cut off Nov17,2021) assessing the real-world effect of glecaprevir/pibrentasvir(G/P) on quality of life (QoL) 1-year posttreatment presented at the European Association for the Study of the Liver Congress 2023
- 01 Oct 2021 Results (n=14357) of an analysis assessing data for all patients who completed a screening visit within any one of the registry phases (phase 1-7) which were based on inclusion of specific HCV therapies in the registry published in the Journal of Viral Hepatitis
- 01 Jul 2021 Results (n=187) assessing real-world effectiveness and safety of 8 weeks of glecaprevir/pibrentasvir in compensated cirrhosis patients and effectiveness in GT3- versus non-GT3-infected patients in the German Hepatitis C-Registry (DHC-R), published in the Liver International.